Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is 8.93% higher on its value in year-to-date trading and has touched a low of $60.63 and a high of $94.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BMRN stock was last observed hovering at around $71.32 in the last trading session, with the day’s gains setting it 0.28%.
Currently trading at $71.60, the stock is 1.36% and 7.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.36 million and changing 0.39% at the moment leaves the stock -2.89% off its SMA200. BMRN registered -14.57% loss for a year compared to 6-month loss of 1.49%. The firm has a 50-day simple moving average (SMA 50) of $66.6992 and a 200-day simple moving average (SMA200) of $73.733.
The stock witnessed a 9.13% gain in the last 1 month and extending the period to 3 months gives it a 9.25%, and is 1.42% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.38% over the week and 2.74% over the month.
Biomarin Pharmaceutical Inc (BMRN) has around 3040 employees, a market worth around $13.66B and $2.84B in sales. Current P/E ratio is 32.55 and Fwd P/E is 17.35. Profit margin for the company is 15.03%. Distance from 52-week low is 18.09% and -24.51% from its 52-week high. The company has generated returns on investments over the last 12 months (6.79%).
The EPS is expected to grow by 43.44% this year
808.0 institutions hold shares in Biomarin Pharmaceutical Inc (BMRN), with institutional investors hold 99.54% of the company’s shares. The shares outstanding are 190.76M, and float is at 188.35M with Short Float at 2.25%. Institutions hold 98.62% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.74 million shares valued at $1.87 billion. The investor’s holdings represent 12.0394 of the BMRN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 18.99 million shares valued at $1.56 billion to account for 10.0569 of the shares outstanding. The other top investors are PRIMECAP MANAGEMENT CO/CA/ which holds 18.79 million shares representing 9.8836 and valued at over $1.55 billion, while DODGE & COX holds 7.3274 of the shares totaling 13.93 million with a market value of $1.15 billion.
Biomarin Pharmaceutical Inc (BMRN) Insider Activity
The most recent transaction is an insider sale by Burkhart Erin, the company’s GVP, Chief Accounting Officer. SEC filings show that Burkhart Erin sold 1,295 shares of the company’s common stock on Mar 19 ’25 at a price of $71.52 per share for a total of $92618.0. Following the sale, the insider now owns 16955.0 shares.
Still, SEC filings show that on Mar 06 ’25, Guyer Charles Greg (EVP, Chief Technical Officer) disposed off 7,034 shares at an average price of $71.28 for $0.5 million. The insider now directly holds 87,655 shares of Biomarin Pharmaceutical Inc (BMRN).
